Gilead will integrate Interius, the first biotech to push an in vivo CAR-T therapy into the clinic, into its cell therapy ...

SANTA MONICA, CA & PHILADELPHIA, PA, USA I August 21, 2025 I Kite, a Gilead Company (Nasdaq: GILD), today announced that it has entered into a definitive ...

Michael J. Sofia, the inventor of the Hepatitis C cure, has joined the Pennsylvania Biotechnology Center in Doylestown, ...

Gilead stock toppled Thursday on a report CVS won't add the company's new HIV prevention drug, Yeztugo, to its commercial plans for now.

Market Catalysts Host Julie Hyman recaps some of the trending tickers on Thursday, Aug. 21, including Coty (COTY), Gilead ...

The Gilead HIV prevention shot , called Yevtugo, is highly effective, but its list price is $28, 218 a year in the U.S.

The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could ...

The Mount Gilead cross country boys picked up a team title Tuesday at the Upper Sandusky Icebreaker Invitational. The team scored 27 points to top the 14-team field. Columbus Grove was second with 48.

The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

Interius is working on a more efficient way to deliver CAR-T therapy to patients. Unlock Digital Access for unlimited access to Inquirer.com and The Inquirer App, plus 5 articles per month to gift to ...

The Handmaid's Tale got people talking right from the start. The show began in 2017 and threw us into Gilead, a scary place where women lose their rights and their names.

Kite Pharma is acquiring Interius BioTherapeutics for $350 million, adding in vivo CAR T technology that could simplify treatment and expand patient access.